These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 21720429

  • 1. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.
    Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev VB, Berk ES, Kapikian R.
    Obesity (Silver Spring); 2011 Sep; 19(9):1796-803. PubMed ID: 21720429
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Pragmatic study of orlistat 60 mg on abdominal obesity.
    Thomas EL, Makwana A, Newbould R, Rao AW, Gambarota G, Frost G, Delafont B, Mishra RG, Matthews PM, Berk ES, Schwartz SM, Bell JD, Beaver JD.
    Eur J Clin Nutr; 2011 Nov; 65(11):1256-62. PubMed ID: 21697820
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Oct; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers.
    Smith TJ, Crombie A, Sanders LF, Sigrist LD, Bathalon GP, McGraw S, Young AJ.
    J Acad Nutr Diet; 2012 Apr; 112(4):533-40. PubMed ID: 22717217
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Computed tomography study of the effect of orlistat on visceral adipose tissue volume in obese subjects.
    Dicker D, Herskovitz P, Katz M, Atar E, Bachar GN.
    Isr Med Assoc J; 2010 Apr; 12(4):199-202. PubMed ID: 20803876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Després JP, Ross R, Boka G, Alméras N, Lemieux I, ADAGIO-Lipids Investigators.
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.